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Abstract
Objectives: It has been shown in early arthritis cohorts that the 2010 ACR/EULAR criteria for rheumatoid arthritis (RA) enable
an earlier diagnosis, perhaps at the cost of a somewhat more heterogeneous patient population. We describe the features
of synovial inflammation in RA patients classified according to these new criteria.
Methods: At baseline, synovial tissue biopsy samples were obtained from disease-modifying antirheumatic drug (DMARD)-
naı ¨ve early RA patients (clinical signs and symptoms ,1 year). Synovial tissue was analyzed for cell infiltration, vascularity,
and expression of adhesion molecules. Stained sections were evaluated by digital image analysis. Patients were classified
according to the two different sets of classification criteria, autoantibody status, and outcome.
Findings: Synovial tissue of 69 RA patients according to 2010 ACR/EULAR criteria was analyzed: 56 patients who fulfilled the
criteria for RA at baseline and 13 who were initially diagnosed as undifferentiated arthritis but fulfilled criteria for RA upon
follow up. The synovium at baseline was infiltrated by plasma cells, macrophages, and T cells as well as other cells, and
findings were comparable to those when patients were selected based on the 1987 ACR criteria for RA. There was no clear
cut difference in the characteristics of the synovium between RA patients initially diagnosed as undifferentiated arthritis and
those who already fulfilled classification criteria at baseline.
Conclusion: The features of synovial inflammation are similar when the 2010 ACR/EULAR classification criteria are used
compared to the 1987 ACR criteria.
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Introduction
Early and aggressive treatment with disease-modifying anti-
rheumatic drugs (DMARDs) is the cornerstone of initial therapy
for rheumatoid arthritis (RA). This therapeutic strategy has been
shown to halt or prevent disease progression and joint
destruction, and thereby improve outcome in RA patients. [1–
3] To be able to start appropriate treatment for the individual
patient, a timely diagnosis and estimation of the prognosis is
required.
In the past years efforts have been made to identify clinical
and molecular parameters that could aid in the diagnostic and/
or prognostic process. [4–7] Recently, ACR and EULAR have
developed a set of new classification criteria for RA that is used
to diagnose early RA. [8,9] The 2010 ACR/EULAR criteria
allow earlier diagnosis of RA, but the clinical picture is slightly
different on the group level, and some patients with self-limiting
disease may be falsely diagnosed with RA. [8,10–12].
As it can be anticipated that the new criteria will be used for
research purposes and since the synovium is the primary target
in RA, we wanted to describe the features of synovial
inflammation in RA patients classified according to the new
2010 ACR/EULAR criteria for RA compared to the use of the
1987 ACR criteria. Therefore, in a prospective cohort study, we
analyzed synovial tissue samples from DMARD-naı ¨ve, early RA
patients in relationship to the use of the different sets of




To analyze synovial tissue samples from DMARD-naı ¨ve,
early RA patients in relationship to the use of the 1987 ACR
RA versus 2010 ACR/EULAR classification criteria, autoanti-
body status, and disease outcome after follow up.
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Since 2002, a prospective cohort of early arthritis patients has
been gathered at the Academic Medical Center/University of
Amsterdam (AMC) in Amsterdam, the Netherlands. This venture
aimed at the identification of novel diagnostic and prognostic
biomarkers has been termed the ‘Synoviomics project’. [13] The
immediate goal of the ‘Synoviomics project’ is to provide insight
into the pathogenesis of various forms of arthritis, especially RA.
From this cohort we selected all patients who fulfilled the 2010
ACR/EULAR criteria for RA already at baseline or after 2 years
follow up [8,9] and from whom synovial tissue samples were
available for analysis. The patients had less than 1 year disease
duration, as measured from the first clinical evidence of joint
swelling, irrespective of which joint was initially affected. Upon
inclusion all patients had active arthritis of at least a wrist, ankle or
knee joint. After inclusion patients were treated by their
rheumatologist. In case of a clinical diagnosis of RA, DMARD
treatment was initiated directly after baseline study procedures
were completed. DAS28 was systematically determined and
patients were treated according to the treat-to-target principle,
aiming for DAS28,2.6. If a combination of DMARDs did not
result in a DAS28,3.2 then a biological was started. Upon
decision of the treating physician corticosteroids were started in
combination with a DMARD, either high dose and tapered down
in 6–8 weeks or continuously low dose, to achieve disease
remission. The patients with undifferentiated arthritis (UA) were
treated with intra-articular steroids, and if arthritis was persistent,
a DMARD was started. In the patients with UA at baseline and
after follow-up (according to the 1987 criteria) 7 patients were
started on DMARD treatment and this was continued during
follow-up in 6 patients.
Ethics
The study was approved by the Medical Ethics Committee of
the Academic Medical Center/University of Amsterdam and
performed according to the Declaration of Helsinki. All patients
gave written informed consent.
Study Design
At baseline, arthroscopic synovial biopsy samples [14] as well as
demographic and clinical assessment data were obtained. At
baseline and after 2 years of follow up a diagnosis was made
according to the 2010 ACR/EULAR criteria (8;9) and according
to the 1987 ACR criteria for RA. [15] After follow up, patients
were also classified according to disease outcome as having self-
limiting disease, persistent non-erosive disease, or persistent erosive
disease. [4] Self-limiting arthritis was defined as absence of
arthritis on examination after follow up, in a patient who had not
taken DMARDs or steroids in the preceding 3 months. Presence of
arthritis in at least one joint and/or treatment with DMARDs or
steroids within the previous 3 months was defined as persistent
disease. Joint destruction was evaluated by the presence or absence
of erosions and joint space narrowing on X-rays of hands and feet
(defined by a score of $1 on the Sharp-van der Heijde erosion/
joint space narrowing score scale [16]).
Disease Activity Parameters
Presence of IgM rheumatoid factor (IgM-RF) and anti-
citrullinated protein antibodies (ACPA) was measured by IgM-
RF ELISA (Sanquin, Amsterdam, the Netherlands) and anti-
CCP2 ELISA (CCPlus, Eurodiagnostica, Nijmegen, the Nether-
lands), respectively.
Patient’s visual analog scale (VAS) for global disease activity
(scale 0–100 mm), VAS for pain (scale 0–100 mm), 68 tender joint
count (TJC68) and 66 swollen joint count (SJC66), morning
stiffness in minutes, erythrocyte sedimentation rate (ESR), and
serum levels of C-reactive protein (CRP) were used to evaluate
disease activity.
Synovial Biopsy Collection, Immunohistochemical
Staining and Quantification
All individuals underwent arthroscopic synovial tissue sampling
of an inflamed wrist, knee or ankle joint. At least six specimens
were collected for immunohistochemistry, as previously described
[17], to correct for sampling error. The synovial biopsy samples
were snap-frozen en bloc in Tissue-Tek OCT (Miles, Elkhart, IN)
immediately after collection. Sections (5 mm each) were cut and
mounted on Star Frost adhesive glass slides (Knittelgla ¨ser,
Braunschweig, Germany). Sealed slides were stored at 280uC
until further use.
Synovial tissue sections were stained in one session specifically
for this study using the following monoclonal antibodies: anti-CD3
(SK7; Becton Dickinson, San Jose, CA) to detect T cells, anti-
CD22 (CLB-B-ly/1, 6B11; Central Laboratory of the Netherlands
Red Cross Blood Transfusion Service, Amsterdam, the Nether-
lands) for B cells, anti-CD55 (67; Serotec, Oxford, United
Kingdom) for fibroblast-like synoviocytes (FLS), anti-CD68
(EBM11; Dako, Glostrup, Denmark) for macrophages, anti-
CD138 (B-B4; Immunotech, Marseille, France) for plasma cells,
anti-tryptase for mast cells (AA1; Dako), anti-von Willebrand
factor (vWF; F8/86; Dako) for blood vessels, anti-CD106/vascular
cell adhesion molecule-1 (VCAM-1; 1G11B1; Sanbio, Uden, the
Netherlands), and anti-vascular endothelial growth factor (VEGF;
C1; Santa Cruz Biotechnology, Santa Cruz, CA).
A three-step immunoperoxidase protocol was used to detect
specific staining for all phenotypic markers and vWF. [18] For
VCAM-1 and VEGF, biotinylated tyramine was used for
amplification, as previously described. [18,19] As a negative
control, irrelevant/isotype-matched immunoglobulins were ap-
plied to the sections instead of the primary antibody or the
primary antibody was omitted. Expression of the synovial
biomarkers was quantified by digital image analysis within one
week after staining, as previously described. [20,21] For each
marker 18 representative high power fields (2.2 mm
2) were
analyzed. Digital image analysis was performed by 3 trained
observers (MS, YS, GS) blinded for clinical classification.
Expression levels of CD3, CD22, CD55, CD68, CD138, and
tryptase are presented as count/mm
2; vWF, VEGF, and VCAM-1
expression levels are presented as integrated optical density (IOD)/
mm




Continuous data are described as median and interquartile
range (IQR). To compare baseline patient characteristics and
expression of biomarkers between the different RA subgroups, the
Kruskal-Wallis test was used when more than 2 groups were
compared; subsequently the Mann-Whitney U test was used to
compare differences between two subgroups. Nominal data were
represented as percentages and analyzed using the Chi
2-test. All
statistical analyses were performed using SPSS v16.0 software
(SPSS, Chicago, IL). A P-value of ,0.05 was considered
statistically significant.
Features of the Synovium in Early Arthritis
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Patients
Synovial tissue samples were available from 69 early RA
patients according to the 2010 ACR/EULAR classification
criteria. Fifty-six of these patients fulfilled the criteria at baseline
and after follow up (RA-RA). Twelve of these patients were not
available for follow up and were therefore excluded from the
outcome analysis. Thirteen patients were initially classified as UA,
but fulfilled the 2010 ACR/EULAR ACR criteria after 2 years of
follow up (UA-RA). This resulted in 69 RA patients for whom
expression of synovial biomarkers at baseline could be related to
diagnosis and autoantibody status, and 57 patients for whom
synovial biomarkers could also be related to clinical outcome after
2 years.
Disease activity parameters and age were significantly different
between the RA-RA and UA-RA groups (Table 1). The overall
median (IQR) disease duration was 4 (6) months. Thirty-three
patients who fulfilled the 2010 ACR/EULAR criteria at baseline
also fulfilled the 1987 ACR criteria for RA after follow-up. In the
RA-RA group with completed follow up data (n=44) 6 patients
had self-limiting disease, 27 had persistent non-erosive disease, and
11 had persistent erosive disease. In the UA-RA group (n=13) 7
patients had self-limiting disease, 4 had persistent non-erosive
disease and 2 had persistent erosive disease (see Figure 1).
The characteristics of the synovium in RA patients according to
the 2010 ACR/EULAR classification criteria are similar to those
when the 1987 ACR criteria are used.
First, we examined the features of synovial inflammation in the
patients who fulfilled the 2010 ACR/EULAR criteria for RA at
baseline but not the 1987 criteria for RA (n=23) in comparison to
patients who fulfilled both the 2010 ACR/EULAR criteria and
the 1987 criteria for RA after 2 years of follow up (n=33) (since
the 1987 ACR criteria have been developed to classify RA in more
advanced disease, we used this as gold standard for RA in this
analysis). In the patients fulfilling only the 2010 ACR/EULAR
criteria for RA there was interindividual variability, but on average
the synovium was characterized by marked infiltration with
macrophages, T cells, plasma cells, B cells and mast cells,
increased numbers of synovial fibroblasts, hypervascularity, and
overexpression of VCAM-1 and VEGF (See Figure 2). The results
were similar to those from RA patients according to the 1987
ACR criteria after 2 years follow up (Table 2).
Second, we selected the patients in our cohort who fulfilled the
2010 ACR/EULAR criteria for RA at baseline (n=56). In these
patients we subsequently applied the 1987 ACR criteria for RA
and analyzed if there were differences between the patients
classified as UA at baseline and after follow up (UA-UA) (n=13),
UA at baseline and as RA after follow up (UA-RA) (n=8) or RA
at baseline and after follow up (RA-RA) (n=25). Of these 56
patients, 10 patients had UA at baseline according to the 1987
criteria but were lost to follow up and therefore could not be given
a definite diagnosis. They were excluded from this analysis. No
statistically significant differences were observed in the numbers of
CD3 positive T cells (P=0.28), CD55 positive FLS (P=0.62),
CD68 positive intimal macrophages (P=0.81), CD68 positive
macrophages in the synovial sublining (P=0.91), CD22 positive B
cells (P=0.58), CD138 positive plasma cells (P=0.48), tryptase
positive mast cells (P=0.61), or expression of vWF (P=0.21),
VEGF (P=0.99), and VCAM-1 (P=0.33) between the 3 patients
groups (Table 3). Together, these data clearly show that the
features of synovial inflammation are on average similar when the
2010 ACR/EULAR classification criteria are used compared to
the 1987 ACR criteria.
Phenotypic and vascular synovial tissue markers do not define
autoantibody status or outcome in RA patients.
Figure 1. Patient classification. Patient classification at baseline and after 2 years follow up according to 2010 ACR/EULAR criteria, and according
to outcome after 2 years follow up.
doi:10.1371/journal.pone.0036668.g001
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related to a specific subset of RA patients, we analyzed the
expression of different phenotypic and vascular markers in RA
patients with and without elevated serum levels of RA specific
autoantibodies. Second, we compared the expression of these
markers in RA patients who developed self-limiting, persistent or
persistent erosive disease after follow up.
No difference in expression of phenotypic or vascular markers
was observed when comparing RA patients according to the 2010
ACR/EULAR criteria for RA upon 2 years follow up with
elevated IgM-RF and/or ACPA levels compared to RA patients
who were autoantibody negative (CD3 positive T cells (P=0.61),
CD55 positive FLS (P=0.29), CD68 positive intimal macrophages
(P=0.73), CD68 positive macrophages in the synovial sublining
(P=0.91), CD22 positive B cells (P=0.63), CD138 positive plasma
cells (P=0.69), tryptase positive mast cells (P=0.60), vWF
(P=0.31), VEGF (P=0.20) and VCAM-1 (P=0.91). Similarly,
no differences were observed when comparing ACPA positive RA
with ACPA negative RA patients or IgM-RF positive RA with
IgM-RF negative RA patients (data not shown).
Of the 69 patients who fulfilled the 2010 ACR/EULAR
criteria for RA after 2 years of follow up, 57 patients could be
classified according to outcome. Thirteen patients had self-
limiting disease, 31 patients had persistent non-erosive disease
and 13 patients had persistent, erosive disease. No statistically
significant differences in cell infiltration, vascularity, and
expression of adhesion molecules were observed between the
different outcome groups (Table 4). Together, these data show
that the synovial tissue markers cannot reliably differentiate
between the subgroups of RA patients.
Table 1. Baseline patient characteristics.
RA ACR/EULAR 2010 P-value
RA (all) (n=69) RA-RA (n=56) UA-RA (n=13)
Age (yrs) 48 (169) 47 (18) 57 (18) 0.03
Dis.dur. (mo) 4 (6) 5 (7) 4 (4) 0.16
Female, n (%) 49 (71%) 40 (71%) 9 (69%) 0.89
VAS global disease activity (0–100 mm) 50 (42) 56 (39) 43 (49) 0.14
VAS pain (0–100 mm) 51 (50) 63 (46) 30 (38) 0.04
MS (min) 30 (55) 45 (75) 1 (15) 0.17
ESR (mm/h) 27 (30) 29 (31) 14 (32) 0.09
CRP (mg/L) 11 (24) 12 (30) 5 (16) 0.02
TJC68 (n) 9 (16) 12 (18) 1 (2) ,0.001
SJC66 (n) 5 (8) 7 (7) 1 (1) ,0.001
RF pos, n (%) 24 (35%) 21 (38%) 3 (20%) 0.05
ACPA pos, n (%) 23 (30%) 23 (41%) 0 (0%) 0.008
Data are presented as median (interquartile range) or number (n [%]), as appropriate. Baseline characteristics were compared between the two diagnostic groups using
a Mann-Whitney U test or a Chi2-test (sex, RF pos, ACPA pos). A P-value of ,0.05 was considered statistically significant (bold). RA=rheumatoid arthritis; RA (all)=all
patients with RA diagnosis after 2 years of follow up; RA2RA=RA at baseline and follow up; UA2RA=initially UA, but definitive diagnosis of RA at follow up;
dis.dur.=disease duration; VAS=visual analog scale; MS=morning stiffness; ESR=erythrocyte sedimentation rate; CRP=C-reactive protein; TJC68=tender joint count;
SJC66=swollen joint count; RF=IgM rheumatoid factor; ACPA=anti-citrullinated protein antibodies; pos=serum positive.
doi:10.1371/journal.pone.0036668.t001
Figure 2. Synovial tissue expression of different cellular markers. Synovial tissue expression of, CD55+ fibroblast-like synoviocytes (FLS),
CD3+ T CD68+ macrophages, CD3+ T cells, CD22+ B cells, CD138+ plasma cells. A:RA patient according to the 1987 ACR criteria, B:RA patient
according to the 2010 ACR/EULAR criteria.
doi:10.1371/journal.pone.0036668.g002
Features of the Synovium in Early Arthritis
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36668Discussion
With the emergence of the 2010 ACR/EULAR criteria more
patients are classified as having RA than with the 1987 ACR
RA criteria in early arthritis cohorts. [10–12] This enables the
diagnosis of RA in patients presenting in early arthritis clinics
with a potentially destructive form of inflammatory arthritis.
However, with these novel 2010 ACR/EULAR criteria not only
patients with a persistent and destructive form of RA requiring
aggressive DMARD therapy are identified but also some
patients with a self-limiting disease. [10] There has been a
recent upsurge in scientific studies of the primary target of RA,
the synovium. As one might wonder if RA according to the
2010 ACR/EULAR criteria on average refers to the same
disease process with the same features of synovial inflammation
as RA according to the 1987 ACR criteria, we sought to
describe these in early RA patients according to the new
classification criteria.
We observed that the synovium of RA patients classified
according to the 2010 ACR/EULAR criteria at baseline is
infiltrated by macrophages, plasma cells, and T cells as well as
other cells like B cells, mast cells, and FLS. In addition, there was
overexpresison of VEGF and VCAM-1, and increased vascularity.
Findings were on average comparable if RA patients were selected
based on the 1987 ACR criteria for RA. When we subdivided the
patients who fulfilled the 2010 criteria into patients who would
have been classified as UA according to the 1987 ACR criteria or
only would have fulfilled the 1987 ACR criteria after follow up,
and those who fulfilled the 1987 ACR criteria already at baseline,
the synovial tissue infiltrate was similar in the three subsets of
patients. This shows that when applying these new criteria on
average similar synovial inflammatory changes are observed
compared to the 1987 ACR criteria for RA. Only few patients
(n=2 [5%]) who were classified as RA according to the 1987
criteria did not fulfill the 2010 criteria at baseline, which is
consistent with previous studies. [10,11].
The results presented here also independently confirm previous
work, showing that the features of synovial inflammation are
similar between autoantibody positive and autoantibody negative
RA [23–25] although such differences have initially been
suggested. [26] The difference in the latter study might perhaps
be explained by differences in disease activity between the two
groups, as patients with ACPA positive RA had on average higher
levels of disease activity in that study.
Our findings do not support the notion that synovial tissue
infiltrate analysis will play an important role in guidance of
treatment decisions in individual early RA patients, as there was
no clear cut difference in baseline features of the synovium
between patients with self-limiting, persistent non-erosive and
Table 2. Expression of synovial phenotypic and vascular
markers in patients who fulfilled 2010 ACR/EULAR criteria for
RA at baseline after follow up and in the patients who
fulfilled1987 ACR criteria.
RA 2010 (n=23) RA 1987 (n=33) P-value
CD3 (count/mm
2) 201(856) 198(795) 0.86
CD55 (count/mm
2) 1,144 (1,253) 1,163 (1,365) 0.89
CD68L (count/mm
2) 274(275) 234 (396) 0.84
CD68SL (count/mm
2) 571 (1,054) 393 (1562) 0.92
CD22 (count/mm
2) 170 (470) 214 (330) 0.94
CD138 (count/mm




235 (445) 338(345) 0.13
vWF (IOD/mm
2) 205,845 (175,450) 171,078 (167,211) 0.75
VEGF (IOD/mm
2) 59,435 (157,527) 63,461 (81,425) 0.86
VCAM-1 (IOD/mm
2) 119,676 (298,344) 184,267 (265,919) 0.70
Values are presented as median (interquartile range). A Mann-Whitney U test
was used to compare the different diagnostic groups; a P-value of ,0.05 was
considered statistically significant. RA=rheumatoid arthritis. CD3 refers to T
cells; CD55– fibroblast-like synoviocytes; CD68– macrophages; CD22– B cells;
CD138– plasma cells; tryptase – mast cells. L=intimal lining layer; SL=synovial
sublining; vWF=von Willebrand factor; VEGF=vascular endothelial growth
factor; VCAM-1=vascular cell adhesion molecule-1. IOD=integrated optical
density.
doi:10.1371/journal.pone.0036668.t002
Table 3. Expression of synovial phenotypic and vascular markers in patients who fulfilled 2010 ACR/EULAR criteria for RA at
baseline subclassified according to fulfillment of 1987 ACR criteria at baseline and after follow up.
RA 2010 ACR/EULAR (n=46) P-value
RA-RA 1987 (n=25) UA-RA 1987 (n=8) UA-UA 1987 (n=13)
CD3 (count/mm
2) 327 (867) 107 (157) 304 (882) 0.28
CD55 (count/mm
2) 1,163 (1,273) 1,514 (1,914) 963 (1,116) 0.62
CD68L (count/mm
2) 256 (458) 139 (150) 229 (456) 0.81
CD68SL (count/mm
2) 491 (1,611) 362 (476) 570 (1,211) 0.91
CD22 (count/mm
2) 198 (389) 233 (286) 407 (598) 0.58
CD138 (count/mm
2) 191 (585) 30 (329) 76 (409) 0.48
Tryptase (count/mm
2) 337 (311) 419 (549) 221 (587) 0.61
vWF (IOD/mm
2) 205,558 (161,492) 93397(181,405) 224,825 (194,340) 0.21
VEGF (IOD/mm
2) 63,659 (96,163) 57,865 (59,901) 55,365 (140,674) 0.99
VCAM-1 (IOD/mm
2) 195,424 (302,882) 96,545 (175,238) 184,647 (322,252) 0.33
Values are presented as median (interquartile range). A Kruskal-Wallis test was used to compare the different diagnostic groups; a P-value of ,0.05 was considered
statistically significant. RA=rheumatoid arthritis. UA=undifferentiated arthritis. CD3 refers to T cells; CD55– fibroblast-like synoviocytes; CD68– macrophages; CD22– B
cells; CD138– plasma cells; tryptase – mast cells. L=intimal lining layer; SL=synovial sublining; vWF=von Willebrand factor; VEGF=vascular endothelial growth factor;
VCAM-1=vascular cell adhesion molecule-1. IOD=integrated optical density.
doi:10.1371/journal.pone.0036668.t003
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on the group level statistically significant differences might be
found in larger studies or if different disease controls would be
included, but to be useful in clinical practice high predictive values
for a specific disease outcome would be needed. In fact, with a
different selection of disease controls, we did observe statistically
significant differences between diagnostic groups (early RA versus
a mixed early non-RA group) on the group level in a previous
study. [7] However, at this moment none of the available tests
would justify the routine use of synovial biopsy in clinical practice
to establish the diagnosis or outcome of RA, except for specific
cases of for instance infection, crystal induced arthritis and
neoplasms. [27].
In conclusion, the characteristics of the synovium are on
average similar in patients classified according to the 2010 ACR/
EULAR criteria for RA compared to those when the 1987 ACR
criteria are used. This information is important for the interpre-
tation of future scientific studies of the synovium using the new
classification criteria.
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